CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Genfit S.A. (GNFTY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Genfit S.A. (GNFTY)

Biological Products, (No Diagnostic Substances) · market cap $447M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Genfit S.A. (GNFTY) is a French biotech with 188 employees and a market cap of approximately $447M at a share price near $8.95. Its disclosed pipeline centers on GFT505 80mg, currently in Phase 2 development for insulin resistance, with limited public detail on mechanism, financials, or upcoming catalysts as of July 2026.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
GFT505 80mgPhase 2Insulin Resistance
Price & technical context
3-month
+66.0%
6-month
+127.2%
12-month
+164.0%
52-wk range
$2.71–$10.00
vs 50-day MA
+22.4%
vs 200-day MA
+78.1%
Realized vol
72.1%
Max drawdown
-57.1%

Daily closes through 2026-03-09. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for GNFTY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.